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Abstract
The immune system is responsible for the defense of the organism. It controls what is
introduced into it and identifies it as self fromnon-self. Thedefensivemechanismsactivated
by the immune system are directed against pathological microbes and toxic or allergenic
proteins, and itmust avoid responses that produce excessive damage of self-tissues, induc-
ing tolerance toavoid autoimmunityandother immunopathologies. RegulatoryTcells play
an essential role in these active processes, using several distinct suppressive mechanisms.
The immune dysregulatory diseases result fromdefects affecting regulatory Tcell develop-
ment and/or function, including the impact of essential genesmutations for Tregulatory cell
functions and the associated autoimmune syndromes.
Keywords: anergy, T cell exhaustion, regulatory T cells, IPEX syndrome, tolerance,
autoimmunity
1. Introduction
The immune system requires strict control and self-regulation in order for its functioning to be
the most efficient possible and adjusted to the defensive needs of each moment, thus inducing
an appropriate immune response against pathogens and tumors. Immune tolerance is based
on the fact that the immune system has to distinguish between itself and any non-self in order
not to destroy its own components, which must be previously recognized as such in the
thymus and bone marrow. When tolerance for some reason fails, multiple pathologies appear,
as autoimmune diseases. In this chapter, we analyze general aspects of dysfunctional T cell
responses such as anergy and T cell exhaustion, some of the phenotypic markers associated
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with them, and the importance of these processes in the establishment of tolerance and
autoimmunity. Also, we consider the main pathogenic event of regulatory T cell dysfunction
leading to multi-organ autoimmunity in the immune dysregulation, polyendocrinopathy,
enteropathy, X-linked (IPEX) syndrome. Clonal anergy, a well-known regulatory mechanism,
can be deemed a hyporeactive state arising when the T cell antigen receptor activates T cells
despite the lack of suitable co-stimulatory signals. T cells have proved to be important in
stimulating and/or maintaining anergy, so the anergic T cells may change their transcriptional
and epigenetic programs and turn into regulatory T cells. Anergic T cells appear to represent
the intermediate reprogramming stage before becoming regulatory T cells, which maintain
self-tolerance. T cell exhaustion is a state phenotypically similar to anergy. When exhausted,
T cells neither secrete cytokines nor lyse target cells, and furthermore fail to proliferate. Such
chronic stimulation prompts the sustained high expression of co-inhibiting molecules, includ-
ing TIM-3, 2B4, PD-1, and LAG-3, which act blocking the activation of T cells. Whereas anergy
is a programmed transcriptional process induced by minimal signaling, exhaustion occurs at
the pathological level by the presence of abundant inflammatory signals maintained over time.
Certain conserved mechanisms promote both anergy and depletion of T cells in the immune
system. The dysfunction of Treg cells is the main pathogenic event leading to the multi-organ
autoimmunity that characterizes the IPEX syndrome, a paradigm of genetically determined
primary immunodeficiency due to mutations of FOXP3, a key transcription factor for naturally
occurring Treg cells, with autoimmunity.
2. Dysfunctional T cell responses
Mechanisms have been developed by the immune system to direct effective responses to a
broad gamut of pathogens. Responses of the immune system protect against many lymphocyte
antigen receptors that are generated by realignments of somatic genes. Although this process
enables hosts to combat pathogens effectively, these organisms quickly evolve to present many
challenges, prompting detrimental immune responses to, for example, self-tissue antigens and
non-harmful components including food antigens or non-pathogenic agents of the intestinal
tract [1]. Various states of T cell dysfunction have been described as a consequence of altered
activation and differentiation processes. Terms such as exhaustion, tolerance, anergy, senes-
cence, and even ignorance have been used to describe the dysfunctional state of T cells,
depending on the clinical settings and the phenotypic and functional features of the T cells.
Autoimmunity, one of the most serious problems of the immune system, causes many dis-
eases that are difficult to cure. One cause of autoimmunity is self-reactive T cells that start to
attack the body of the host in the periphery [2, 3], although most self-reactive immature
T cells are eliminated by negative selection in the thymus [4]. Multiple mechanisms are at
work to prevent autoimmunity, including regulatory T cells [5], T cell ignorance [6], and T cell
anergy [7]. The development the other pathologies such as chronic infections and cancer
is facilitated by a variety of immune-subversion mechanisms, with the production of anti-
inflammatory cytokines, induction of regulatory T (Treg) cells, and expression of immune
checkpoint molecules.
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3. Regulatory T cells
Regulatory cells (Tregs) play a critical role in the establishment and maintenance of immune
homeostasis as well as in the limitation of chronic inflammatory responses directed against
pathogens and environmental factors [8–10]. This cell-mediated suppression is considered a
vital mechanism of negative regulation of immunomediated inflammation, and plays a prom-
inent role in autoimmunity and auto-inflammatory disorders, allergies, acute and chronic
infections, cancer, and metabolic inflammation; these are important candidates for the thera-
peutic treatment in these inflammatory and autoimmune diseases.
Treg cells represent 5–10% of peripheral CD4+ T cell compartment in humans. In this section, we
present the characteristics that define regulatory T cells, the phenotypic and functional heteroge-
neity that they present, with particular reference to the consequences of T cell dysfunction in
contributing to the development of autoimmunity and deregulation of the immune system [11].
3.1. Treg phenotypes
Treg cells represent highly differentiated populations in that they are distinguished pheno-
types based on the expression of specific markers and mechanism of action. Different Treg
subsets have been identified, but two major types expressing Foxp3+ transcription factor can
be distinguished based on their origin: (i) natural or Treg cell thymus-derived (nTreg or tTreg)
and (ii) induced Tregs that develop in the periphery from naïve conventional CD4+ T cells
(iTregs or pTregs) [12, 13]. The nTregs are the major mediators of central immune tolerance,
whereas iTregs are involved in the regulation of peripheral immune tolerance in sites of
inflammation [14].
The phenotype as well as function of nTregs, as opposed to iTregs, have been difficult to study in
humans, given the shortage of markers used for discriminating these cell types. It has recently
been argued that the expression of Helios, which is a transcription factor of the Ikaros family, can
discriminate nTregs from iTregs on the basis of most thymically derived FOXP3+ cells expressed
by Helios [15]. Nevertheless, the Helios used as a marker for nTregs has been disputed because,
depending on the cell-activation conditions, Helios is also expressed in conventional T cells
(T conv) of humans [16]. Helios cannot be used as an nTreg/iTreg discrimination marker but
may serve as a useful activation/differentiation marker for Tregs. In this sense, the subset of
nTreg cells could be subdivided on the basis of Helios expression, representing a stable and
suppressive Treg population that differs only in cytokine/chemokine production [17].
Other Treg cells are found in the periphery, such as Tr1 cells, which lack the expression of the
transcription factor FOXP3 [18] with immunosuppressive functions as IL-10 and TGF-β secre-
tion [19], and Th3 cells with a variable level of FOXP3 expression [20]. CD8+CD25+ Treg cells
are also developed in the thymus, expressing several molecules characteristic of nTregs,
namely CD25, FOXP3, CTLA-4, and TNF-receptor. CD8+CD28+ Tregs inhibit priming of CD8
+ and CD4+ T cells, and antibody-mediated against oral antigens. CD8+CD28-Tregs can be
induced from naïve CD8+ T cells upon activation by allogenic antigen presentation cells
(APCs) in the presence of IL-2 and granulocyte-macrophage colony-stimulating factor (GM-
CSF). The γδ T cells are commonly of the CD8 + FOXP3-phenotype and are found mainly in the
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intestinal epithelium associated with mucosal tolerance. These cells can also regulate autoim-
munity and tumor immunity by producing IL-10 and TGF-β, similarly to Tr1 cells [21].
3.2. Treg functions
Treg cells have been considered key players in dominant immune tolerance [22]. Treg cells
have performed functions such as to suppress inflammatory responses in mucosal interfaces
that are constantly exposed to allergens [23], commensal gut microbiota [24, 25], transplanted
organs [26], pathogenic infections [24], and tumors [27]. Recent studies have suggested a role
for Tregs in other situations, such as adipose tissue resident Tregs controlling metabolic disor-
ders [28, 29] and Tregs limiting organ rejection [30]. In certain cases, the suppressive function
of Tregs limits beneficial effector responses of the host against tumors and chronic infections
[31, 32]. Hence, the activities of this suppressive population need to be controlled by allowing
the balance between restricting deleterious inflammatory and autoimmune insults, while
facilitating protective responses against infections and tumors.
While FOXP3 is an indispensable transcription factor to define the majority of the Treg tran-
scriptional and functional subsets, FOXP3+ Treg cells express on the cell surface high levels of
interleukin-2 receptor α (CD25) and a low level of IL-7 receptor α (CD127) [33]. Thus, the
majority of Treg cells constitutively express high levels of the inhibitory molecule cytotoxic
T lymphocyte-associated antigen 4 (CTLA4) and the glucocorticoid-induced TNFR family
related (GITR), as well as the regulatory cytokines IL-10 and TGF-β [34–36].
According to a number of studies, not all FOXP3+ Tcells are functional Tregs, and it is possible to
induce a portion of the Treg signature without the presence of FOXP3 [37, 38] since activated
human T cells express Foxp3 transiently without acquiring suppressor capacity [39, 40] The
essential aspect of the Treg cell (FOXP3 expression and suppressive capability) can be
maintained in differing Treg sub-populations identified in various anatomical locations as well
as under pathological conditions [41–43]. Their characteristics allow phenotypic/functional
adaptation to block full immune responses. Within the FOXP3+ Treg subsets, the diversity can
be characterized by: (i) differential transcription-factor expression [44–47]; (ii) different expres-
sion of chemokine receptors [41, 42, 47], and (iii) differing expression of suppressor markers that
control various types of target cell in diverse environmental and pathological conditions [48–50].
Treg cells, on losing FOXP3 expression as well as their suppressive capability, form an unstable
population, taking on characteristics similar to those of the effector T cell reacting to environ-
mental cues [51–53]. Though convincing evidence is available for Treg cell stability under healthy
immune conditions [54, 55], numerous studies propose that inflammatory conditions may be
related to downregulation/loss of FOXP3, secretions of effector cytokines, and also the prolifera-
tion of the so-called “ex-Treg” cells [13, 56]. This implies that Treg cells may be reprogrammable
as inflammatory cells in reaction to microenvironmental signals. Treg cells show no terminal
differentiation, though they do retain plasticity and can differentiate into specialized hybrids to
control immune responses [57]. Thus, for Treg function, two models have been proposed: one in
which Treg-specific expression of FOXP3 would encode the expression of Treg suppressor
characteristics (greater CD25 and CTLA-4), whereas their ability to adapt to the shifting environ-
mental cues would induce further suppressive modules (e.g. miRNAs, suppressive pathways,
transcription factors, and chemokine receptors) for suitable immune regulation [58].
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Another key question is the role of Treg cells in preventing autoimmunity and their therapeutic
potential based on Treg cell transfer or activation leading to the definition of the signals
responsible for generating and maintaining of Treg cells [59]. Several studies have focused on
two sets of signals—interleukin-2 (IL-2) and antigen itself [60, 61]. Thus, IL-2 is required for the
survival of Treg and for maintaining their functional activity by promoting expression of
FOXP3 and mediators of suppression, particularly CTLA-4 [62]. Answers to environmental
antigens may provide enough IL-2 to maintain a Treg cell repertoire in healthy individuals. The
dependence of Treg cells based on IL-2 received from conventional T cells provides a negative
feedback through which the ratio of Treg cells and conventional T cells is controlled [63].
3.3. Regulatory T cells and tolerance
Oral tolerance to foods is an active immunological process that involves allergen-specific Treg
cells [64–66]. Genetic and immunological evidence supports an important role for Treg cells in
enforcing oral tolerance to foods [67–69]. This tolerance depends on iTreg-cell development
from naïve conventional CD4+ T cells (CD4+ Tconv), which are activated in presence of TGF-β1
and CD103+ dendritic cells (DCs) [70–72] regulating T helper 2 cell responses at the mucosal
surfaces [73, 74]. In food allergy, a deficient formation and impaired function of allergen-
specific Treg cells is present.
Treg cells in the intestine are important in bringing about a tolerogenic environment for
maintaining immune homeostasis in commensal bacteria [75, 76]. The question of commensal
bacteria-inducing Treg and effector cells is basic in explaining the way in which the immune
system receives instructions from particular species of bacteria and in determining the dynam-
ics of Treg versus effector-cell selection of bacterial antigens [77–79]. T cell differentiation may
be guided by innate stimulators of commensal bacteria as TLRS selectively activate cytokine
production from APC subsets, TLRS being major sensors capable of recognizing conserved
molecular motifs in bacteria [80, 81]. However, the adaptive immune system may react to
pathogenic rather than commensal bacteria, so that the pre-existing effector and Treg cell
reactions to commensal bacteria may alter the course of the infection. In addition, infection
may upset the balance between effector versus Treg cell reactions to commensal bacteria,
disturbing immune homeostasis as well as potential immunopathology [75, 80].
A dynamically regulated Treg cell population would be in tune with the commensal micro-
biota and thus would be more responsive when confronted with a strong influx of commensal
antigens after mucosal injury, limiting the activation of effector T cell, and controlling excessive
inflammation [75–77]. By contrast, bacteria new to the digestive system would not trigger Treg
or effector T cells already present, but rather would need a new selection of effector versus
regulatory T cell reactions. This situation would enable quicker effector responses to microbes,
limiting the generation of effector T cells meeting commensal bacteria, and this could prompt
inflammatory bowel disease (IBD) development [82].
Commensal bacteria are major initiators of effector T cell reactions that lead to inflammation.
The immune system responds to commensal antigens as non-self, not only because bacterial
antigens are unlikely to be present during the selection of thymic T cells, but also because
bacteria bear a number of ligands used in recognizing immune receptors [83]. It is widely
accepted that commensal bacteria also induce T cells that decrease inflammation in order to
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sustain intestinal tolerance. Thus, Treg cells play a vital part in maintaining homeostasis of the
gut immune system and in deterring effector cells from triggering immunopathology as a
response against commensal bacteria.
Several studies have identified microbial products from a specific bacterial species that affects
Treg cell function. Polysaccharide A (PSA) from Bacteroides fragilis was found to activate TLR2
expressed on Treg cells, inducing the production of IL-10 [84], facilitating the persistence of B.
fragilis. Many studies have reported a possible “universal”mechanism driving Treg cell expan-
sion that is mediated by bacterially derived short-chain fatty acids (SCFAs) produced through
the metabolism of dietary fiber [85–87]. The microbial products are perceived by the intestinal
immune system to facilitate homeostasis and tolerance instead of inflammation, consistent
with the notion of an evolutionary mutualistic relationship between commensal bacteria and
the host [84, 88]. In this sense, colonic Treg cells utilize a unique set of T cell receptors (TCRs),
suggesting that they recognize antigens found only in this tissue including colon-specific self-
antigens and antigens derived from commensal bacteria [89].
Alterations in the composition of commensal bacterial populations are linked to multiple
metabolic and inflammatory diseases including, but not limited to, inflammatory bowel dis-
ease (IBD), obesity, type 2 diabetes, atherosclerosis, allergy, and colon cancer [90–92]. Recent
studies have identified a critical role for commensal bacteria and their products in regulating
the development, homeostasis, and function of innate and adaptive immune cells [93–95].
However, an emerging and interesting area that has received relatively little attention is how
metabolites and nutrients derived from commensal bacteria regulate the host immune system.
4. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked
(IPEX) syndrome
As discussed above, Treg cells play a key role in immune homeostasis by maintaining a
balanced adaptive immune response. The spectrum of manifestations due to Treg cell defect
might range from mild allergy or autoimmunity to lethal immune dysregulation disorders
(IPEX) [96]. Several human genetic disorders have recently been described and noted to have
an extraordinary impact on Treg cell development and functional activity [97]. A loss of
function mutation in FOXP3, the key transcriptional factor for Treg cell differentiation, leads
to an IPEX phenotype. Subsequently, a number of other gene defects have been reported to
cause IPEX-related phenotypes, including the loss of function mutations in theCD25, STAT5B,
LRBA, and CTLA4 gene [98].
IPEX, a rare genetic disorder, results from a dearth of functional Treg cells caused by losses of
function mutations in FOXP3. It affects only males because of its X-linked recessive inheri-
tance. Also, it is frequently fatal in the early years of life if the patient receives no bone marrow
transplant [99]. In clinical terms, IPEX presents three maladies: autoimmune enteropathy,
autoimmune endocrinopathy, and eczematous dermatitis. The most frequent manifestation,
enteropathy, gives way to endocrinopathy particularly insulin-dependent type 1 diabetes
mellitus [99]. Other manifestations include lung disease, immune-mediated cytopenia,
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autoimmune nephropathy, anemia and/or thrombocytopenia, and hepatitis. Furthermore,
food allergies with high serum IgE and peripheral eosinophilia prove very common, indicating
a clear failure of oral tolerance in this disorder. Usually, IPEX patients show a broad range of
autoantibodies because of adaptive immune dysregulation. With over 60 FOXP3 mutations
reported up to now, observations from the clinical phenotype reported for these mutations
have led to postulations of genotype/phenotype relationships [100].
CD25 deficiency properties shared with IPEX include chronic eczema, enteropathy, lympho-
proliferation, and autoimmunity disorders such as alopecia, diabetes mellitus, thyroiditis, and
autoimmune hemolytic anemia [101–103]. CD25 deficiency is permissive to Treg cell differen-
tiation, with normal count of FOXP3+ Treg cells found in circulation [104]. The loss of CD25
expression impairs Treg cell suppressive function by defective production of suppressive
cytokine IL10. Their failure deprives Tconv cells of IL-2 production, leading to their apoptosis
[62, 101]. Finally, the decreased sensitivity of CD25-deficient Treg cells to IL-2 impairs their
metabolic competence in the context of an immune response [105, 106].
Evidence from studies on human and murine models show that Type-1 regulatory T (Tr1) cells
can contribute to suppressing the development of autoimmunity in addition to nTreg cells
[106, 107]. Tr1 cells can develop in IPEX patients regardless of FOXP3 expression [108]. This
observation suggests that FOXP3-independent immune regulation can potentially help control
the disease, although Tr1 cells alone do not seem adequate to suppress the initial acute phase
of the disease.
5. T cell exhaustion
T cell exhaustion is distinguishable from other dysfunctions such senescence or anergy, based
on molecular mechanisms [109, 110]. That is, exhausted T cells come from cells that initially
developed an effector function but then gradually lose it because of continuous stimulation of
the T cell receptor (TCR) from the persistent antigen helping to build peripheral tolerance as
well as to modulate immune responses [111, 112]. As such, exhausted T cells present in
patients having autoimmune disorders correlate with positive prognoses [113]. However, in
cancers, exhausted T cells may block tumor clearance, thereby contributing to immune escape
[114, 115]. This also leads to chronic infections, and viral immune evasion results from the
persistence of activated T cells that have no effector function [116].
Regarding the origin of exhausted T cells, recent work has shown that exhausted CD4+ and
CD8+ T cells bear a notably different transcriptional profile from that of effector and memory
CD4+ or CD8+ T cells. These differences include shifts in the expression of co-stimulatory and
inhibitory receptors (IRs), as well as signaling molecules, transcription factors, chemokines
receptors, cytokines, and genes that are involved in metabolism. Also, genomic research
supports the contention that exhausted T cells constitute a unique stage of T cell differentiation
[110, 117].
With respect to the causes behind T cell exhaustion, CD8+ T cell exhaustion likely involves
altered inflammatory and tissue microenvironments as well as other populations of
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lymphocytes such as CD4+ T cells, regulatory T cells, B cells, and inhibitory cues from cyto-
kines and inhibitory as well as co-stimulatory cell-surface receptors [110]. The major feature
appears to be a chronic and presumably continual antigen exposure instead of acutely termi-
nated or intermittent exposure. Also, the severity of the exhaustion and the deletion of antigen-
specific T cells have been found to correlate with (i) the expression of stimulatory and inhibi-
tory receptors; (ii) the levels of stimulatory and suppressive cytokines; and (iii) the degree of
antigen stimulation [118, 119].
The gradual dysfunction of exhausted T cells is accompanied by the expression of multiple
inhibitory receptors, by progressive loss of IL-2 production and TNF-α and IFN-γ depletion
[112], as well as by altered cell metabolism with a markedly different transcriptional profile
[120, 121]. T cells do not exhaust uniformly during chronic diseases or cancer, but instead
specific subsets with different memory and proliferative potentials emerge after exposure to
persistent antigen [122, 123].
While exhaustion was first viewed as a dysfunctional T cell state, this phenotype is now
considered an appropriate response to chronic infection, because a persistent effector function
could cause excessive damage to healthy cells. T cell exhaustion prevents optimal control of
infection and tumors, modulating pathways overexpressed in exhaustion that can reverse this
functional state and reinvigorate immune responses [124] by targeting programmed cell-death
protein 1 (PD1) and cytotoxic T lymphocyte antigen 4 (CTLA4) [125, 126]. Exhausted T cells are
not inert, given that they retain crucial functions at the suboptimal level that limits ongoing
pathogen replication or tumor progression. These cells are not effective at eradicating patho-
gens or tumors, and have been considered of interest in avoiding or reversing exhaustion.
Inhibitory receptors (IRs) are negative regulatory pathways that control autoreactivity and
immunopathology and are transiently expressed in functional effector T cells during activa-
tion. A higher and sustained expression of inhibitory receptors is a hallmark of exhausted
T cells. The molecular mechanisms by which inhibitory receptors control T cell exhaustion are
not entirely known. Although PD1 is the best characterized inhibitory receptor, exhausted
T cells express a range of other cell-surface inhibitory molecules to impair T cell responses
during chronic infections, such as CTLA4, LAG3, 2B4, TIM3, CD160, and many others [127].
The co-expression of multiple inhibitory receptors is a chief feature because the simultaneous
blockage of IRs results in synergistic reversal of T cell exhaustion. Results of several clinical
trials using immune checkpoint inhibitors are very encouraging. Blocking antibodies for
CTLA-4, PD1, and PDL1 appear to have a strong therapeutic potential given alone or in
combination with standard treatment in many tumors.
In addition, the soluble molecules regulate T cell exhaustion. These include immunosuppres-
sive cytokines such as IL-10, TGF-β, and inflammatory cytokines such as IFNs type I and IL-6
[110]. Blockage of IL-10 restores T cell function and improves viral control during chronic viral
infections, demonstrating that IL-10 promotes T cell exhaustion [128, 129]. Many cell types can
be the source of IL-10 during chronic infection, including dendritic cells (DCs), monocytes, and
CD4+ T cells [130, 131]. The blocking of IL-10 and the PD1 pathway in a simultaneous manner,
synergistically reverses CD8+ T cell exhaustion and enhances viral control, indicating a role for
IL-10 in controlling CD8+ T cell exhaustion [132]. Depletion of CD4+ T cells help during
pathogen persistence and can contribute to defective CD8+ T cell responses. Therefore, in HIV
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infection, the loss of the CD4+ T cell response can result in exhausted CD8+ T cells and disease
progression [133].
6. T cell anergy
Immunological tolerance is the essential mechanism for maintaining immune homeostasis. T
cell anergy, one of the major mechanisms involved in immunological tolerance [134–136], is a
hyporesponsive state of T cells under antigen stimulation. The expression of several anergy-
specific genes are known to change in anergic T cells, such as DGK-a, an intracellular signaling
molecule (also known as an anergy-related gene) and EGR2, a transcription factor, and this
reportedly increases in anergic T cells [137, 138]. However, the degree of contribution and
relevance of each anergic gene and the mechanism of this gene regulation are not understood.
It is known that the increased expression of anergic genes is maintained over the long term.
However, it seems unlikely that every gene associated with anergy induction would be epige-
netically regulated, because there are too many genes with an altered expression level in
anergic T cells to be independently regulated [139, 140].
Effective mechanisms of peripheral tolerance are required to eliminate circulating autoreactive
T cells and thereby prevent undesired immune responses against self-antigens. The key players
in this process are DCs, which induce tolerance by different control mechanisms such as T cell
deletion, the generation of Tregs, and/or the induction of anergy [141, 142]. Interaction between
DCs and T cells occurs through three independent signals: (i) recognition of peptide-MHC
complexes presented on DCs via specific TCR on T lymphocytes, (ii) binding of co-stimulatory
molecules expressed on DCs to their respective receptors on T cells, and (iii) polarizing cyto-
kines secreted by DCs [143]. When antigen peptides are presented by DCs in the absence of
co-stimulation, T cells become anergic [144].
The induction of T cell anergy occurs when negative signals acquire more weight than the
activatory signals from APCs. Anergy was originally defined as an unresponsive state provoked
in T cells recognizing an antigen without co-stimulatory signals [145], normally when CD28 on T
cells binds to its ligands, that is, B7 molecules, and expresses on DCs [146]. As a result, T cell
proliferation and cytokine production are impaired when the same antigen is encountered again.
Anergy also results from coinhibitory signals by PD-1 or CTLA-4 receptors [147, 148]. The latter
interacts with B7 molecules, with preference toward CD80, whereas PD-1 binds to PD-L2 and/or
PD-L1 ligands on DCs. Furthermore, adenosine from tissue, acting by the adenosine A2A
receptor (A2AR), acts as another key negative regulator for the activation of T cells, having the
ability to drive long-term anergy, even with co-stimulation [149]. Therapies known as the
“checkpoint blockade” treat cancer patients using blocking antibodies against those receptors.
This approach is clinically quite promising given that blocking antibodies can alleviate
hyporesponsiveness and encourage the rejection of tumors. Unraveling this process is the focus
in designing therapies to counteract autoreactive T cells involved in autoimmune diseases [150].
Treg cells, important for inducing and/or maintaining anergy and anergic T cells, can in turn alter
their epigenetic and transcriptional programs to become Treg cells [151]. Anergic T cells may
represent the intermediate reprogramming stage before they themselves become surveying Treg
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cells that maintain self-tolerance. T cell anergy and Treg induction are crucial mechanisms for re-
establishing tolerance [152], and although presenting different phenotypic and functional char-
acteristics, both mechanisms have in common the expression regulation of some genes, such as
PD-1, ICOS, LAG3, CTLA-4, EGR2 [151], GRAIL [152, 153], CBL-B, and ITCH [154, 155].
The suppression of antigen-specific T cell responses either through the expansion of Tregs or
the induction of anergy represents an attractive immunotherapeutic approach to target
autoreactive T cells in autoimmune diseases [156]. The generation of Tregs has been of interest,
but Tregs can exert unspecific regulation and may be prone to conversion into proinflam-
matory Th17 cells [157]. By contrast, the induction of a stable hyporesponsive state appears to
be a promising strategy to specifically silence self-reactive T cells in autoimmune diseases
without undesired adverse effects. In vivo anergy induction in autoreactive CD4+ T cells has
been demonstrated to control disease onset and progression in murine models of autoimmune
diseases [158]. The possibility that anergic T cells can also acquire suppressive capacities
supports their fundamental role in the control of immune responses. Thus, T cell anergy is an
effective mechanism to eradicate aberrant T cell responses to “self” and for the reestablishment
of self-tolerance in patients with autoimmune diseases [159, 160].
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